This federal Project Grant award in the amount of $469,830.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The grant aims to identify oral bacterial species with anti-cancer properties and evaluate their potential for preventing or treating oral squamous cell carcinoma (OSCC). Specifically, the study will assess the effects of Streptococcus mitis and Haemophilus parainfluenzae on OSCC...
This $598,332 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) program, will support research to investigate the role of the truncated TrkB isoform (TrkBT1) in oral cancer pain. The primary awardee, the University of Texas Health Science Center at San Antonio (UTHSCSA), will conduct studies to examine how TrkBT1 expressed in trigeminal sensory neurons and oral squamous cell carcinoma (OSCC)...
This Project Grant award, totaling $390,000.00, was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research (CFDA 93.121) federal grant program. The primary objective is to leverage single-cell co-culture and gene expression profiling to identify tumor antigen-specific T cells in oral squamous cell carcinoma (OSCC). Key products and services to be delivered include: Optimizing a high-throughput, single-cell co-culture system...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research Federal Grant Program (CFDA 93.121), provides $808,264 to The Medical University of South Carolina to conduct research on the mechanisms of filopodia-mediated intracellular delivery of small interfering RNAs (siRNAs) via peptide carriers. The goal is to elucidate the mechanisms underlying filopodia-directed cell entry of the RD3AD-siRNA complex in...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $204,688 to The Johns Hopkins University to develop a novel immunotherapy approach for treating HPV-associated head and neck cancers. The key products and services to be delivered under this award include: 1) Evaluating the ability of Salmonella-derived nanoparticles coated with the HPV E7 antigen (SOMV-9RE7) to induce...
The federal Project Grant award of $1,403,398 was granted on September 2, 2024 by the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research Federal Grant Program (CFDA 93.121). The award supports research aimed at utilizing advanced imaging approaches to develop imaging-based biomarkers related to the hybrid epithelial/mesenchymal state (HEM) and its interactions with the immune system in head and neck squamous cell carcinoma (HNSCC)....
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), funded under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to study essential genes in the oral pathobiont Fusobacterium nucleatum. The $429,000 award to the University of Texas Health Science Center at Houston aims to investigate the molecular basis for the essentiality of the FomA gene and systematically identify other essential genes in F. nucleatum. The goal...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) program, is funding the development of salivary peptide/protein-based multilayer coatings for dentures to control Candida biofilm formation and denture stomatitis. The key objectives are to: (1) fabricate rat dentures with salivary anticandidal peptide/protein-based multilayer coatings; (2) evaluate the anticandidal activity and...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $2,805,385 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to Oregon Health & Science University (OHSU). The grant aims to define the T cell-based mechanisms underlying oral mucosal immune-related adverse events (irAEs) caused by anti-PD-1 cancer immunotherapy, with the goal of developing strategies to mitigate these side effects. The research will utilize human samples, mouse...
This $626,893 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the University of Texas MD Anderson Cancer Center will fund research to study the role of bacterial-colonized microniches within tumors and their impact on intratumoral heterogeneity. The research aims to: 1) functionally map the cellular and metabolic features of these bacterial microniches within patient tumor tissues, 2) delineate the human cell types harboring intracellular...